Solifenacin succinate (C007B-272077)

InformationSolifenacin succinate (YM905) is a urinary antispasmodic of the antimuscarinic class.In vitroSolifenacin succinate is a new muscarinic receptor antagonist developed for the treatment of overactive bladder. The affinity constants (pKi) of solifenacin for recombinant human muscarinic M1, M2 and M3 receptors are 7.6, 6.9 and 8.0, respectively. Hence, the muscarinic M3 receptor subtype selectivity of solifenacin over the muscarinic M2 receptor subtype is readily apparent, but is only marginal over the muscarinic M1 receptor subtype. In the same study, solifenacin and oxybutynin inhibit muscarinic M3 receptor-mediated intracellular Ca2+ mobilization in bladder smooth muscle cells isolated from guinea pigs and in submandibular gland cells isolated from mice.In vivoCell Datacell lines：Concentrations：Incubation Time：Powder Purity:≥99%.

Specifications and Purity: 10mM in Water

Molecular Formula: C23H26N2O2·C4H6O4

Molecular Weight: 480.55